- Home
- OCGN vs ALDX Comparison
OCGN vs ALDX Comparison
Compare OCGN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- ALDX
- Stock Information
- Founded
- OCGN 2013
- ALDX 2004
- Country
- OCGN United States
- ALDX United States
- Employees
- OCGN N/A
- ALDX N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- ALDX Health Care
- Exchange
- OCGN Nasdaq
- ALDX Nasdaq
- Market Cap
- OCGN 321.7M
- ALDX 313.4M
- IPO Year
- OCGN N/A
- ALDX 2014
- Fundamental
- Price
- OCGN $1.79
- ALDX $5.62
- Analyst Decision
- OCGN Strong Buy
- ALDX Strong Buy
- Analyst Count
- OCGN 3
- ALDX 2
- Target Price
- OCGN $6.00
- ALDX $9.50
- AVG Volume (30 Days)
- OCGN 7.9M
- ALDX 715.0K
- Earning Date
- OCGN 11-07-2025
- ALDX 11-06-2025
- Dividend Yield
- OCGN N/A
- ALDX N/A
- EPS Growth
- OCGN N/A
- ALDX N/A
- EPS
- OCGN N/A
- ALDX N/A
- Revenue
- OCGN $4,754,000.00
- ALDX N/A
- Revenue This Year
- OCGN N/A
- ALDX N/A
- Revenue Next Year
- OCGN N/A
- ALDX $36.23
- P/E Ratio
- OCGN N/A
- ALDX N/A
- Revenue Growth
- OCGN N/A
- ALDX N/A
- 52 Week Low
- OCGN $0.52
- ALDX $1.14
- 52 Week High
- OCGN $1.90
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- OCGN 70.01
- ALDX 60.71
- Support Level
- OCGN $1.31
- ALDX $5.13
- Resistance Level
- OCGN $1.85
- ALDX $5.78
- Average True Range (ATR)
- OCGN 0.14
- ALDX 0.22
- MACD
- OCGN 0.02
- ALDX 0.07
- Stochastic Oscillator
- OCGN 78.81
- ALDX 88.00
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.